FDAsafety guidance66% confidence
FDA AP — FERRIC CARBOXYMALTOSE (ORIG)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Mylan; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application ANDA212572. Sponsor: MYLAN LABS LTD. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: FERRIC CARBOXYMALTOSE.
Supporting Context
- Therapeutic area
- Oncology · Small Molecule
- Sub-indication
- General
Related signal: FDA Grants AP Status for Lenalidomide ANDA213912 by Mylan